Alvotech
Alvotech is a U.S.-listed biotechnology company focused on developing and manufacturing biosimilar medicines. Its business combines biosimilar research and development, regulatory approval activities, and commercial supply through partnerships in key markets, with operations spanning multiple regions.
Fiscal year 2025 · change from previous year
Development 2024–2025
Business
Share of revenueDevelopment programs for biosimilar versions of branded biologic medicines.
Manufacture and supply of approved biosimilar products to partners and markets.
Upfront, milestone, and ongoing value tied to partnered product rights.
Customers
Alvotech sells into a partner-led pharmaceutical commercial model, so its direct customers are primarily licensing and commercialization partners rather than end patients. Those partners include companies that market biosimilars in the U.S. and selected international markets, while healthcare systems and patients are the ultimate end users of the medicines. The company also interacts with regulators and contract manufacturing/commercialization counterparties as part of its product launch model.
Pharma partners that license or co-commercialize Alvotech biosimilars in exchange for market access and execution support.
Local partners that handle regulatory submissions and commercialization in specific countries or regions.
Hospitals, clinics, and payers that use biosimilars because they can lower treatment costs versus branded biologics.
Patients receiving biosimilar therapies for oncology, immunology, or rare-disease indications through the healthcare system.
Strategy
Alvotech’s strategy centers on building a biosimilar portfolio, securing regulatory approvals, and expanding commercialization through third-party partners. The company also seeks to capture more value from its development and manufacturing platform through direct participation in U.S. commercialization for selected products and by extending reach into Asia through regional agreements.
A larger approved portfolio is necessary to scale supply, partner value, and future revenue opportunities.
The company depends on partners for market access and local execution in markets where it lacks its own commercial infrastructure.
Regional deals diversify access to large markets without requiring full local sales builds.
Exclusive supply arrangements can convert development success into recurring product supply revenue.
Geography
Alvotech operates on a global basis and reports in U.S. dollars, while its business involves multiple currencies and market regions. The company’s partnerships and commercialization rights extend across the United States and selected Asian markets, and its operating exposure includes Europe, Iceland, the U.K., Switzerland, and other international markets tied to development and supply. Geography matters because regulatory approval, commercial access, and foreign-exchange exposure all vary by market.
Risks
Alvotech faces the normal risks of a biosimilar developer: clinical and regulatory uncertainty, intense competition, and dependence on partners to commercialize approved products. Its reported accounting weaknesses, judgment-heavy development capitalization, and foreign-currency exposure add operational and reporting risk, while manufacturing and supply execution remain critical to converting approvals into revenue.
- Development and regulatory uncertaintyImpact: HighLikelihood: High
Biosimilar programs require successful preclinical, clinical, and regulatory steps before commercialization.
Exposure: Pipeline candidates and approval timelines
- Partner dependenceImpact: HighLikelihood: High
Alvotech relies on third parties for commercialization and market access in many markets.
Exposure: U.S. and selected Asian commercialization arrangements
- Competitive pressureImpact: HighLikelihood: High
Biosimilars compete against both branded originators and other biosimilar developers in regulated markets.
Exposure: Oncology and specialty biologics
- Manufacturing and supply chain executionImpact: HighLikelihood: Medium
The business must reliably supply product after approval, and disruptions can delay revenue and damage partner relationships.
Exposure: Global production and distribution
- Internal control weaknessesImpact: MediumLikelihood: High
Management disclosed material weaknesses in internal control over financial reporting.
Exposure: Financial reporting processes
- Foreign exchange volatilityImpact: MediumLikelihood: High
The company transacts in multiple currencies while reporting in U.S. dollars.
Exposure
Accounting
Judgemental itemsThe company capitalizes biosimilar development spend when technical feasibility and future benefits criteria are met.
Impact: Can materially shift expenses into assets and affect earnings timing
Partner deals may include upfront fees, milestones, and supply revenue with different timing rules.
Impact: Affects when collaboration and product revenue is recognized
Valuation changes can create finance income or expense volatility.
Impact: Can swing reported finance costs and net results
Control deficiencies increase the risk of misstatement or delayed reporting.
Impact: Affects confidence in reported financial statements
Similar listed companies
Publicly listed companies with a comparable business focus.
Avalo Therapeutics, Inc.
AVTX · Pharmaceutical Preparations
BioNTech SE
BNTX · Biological Products, (No Diagnostic Substances)
BioNTech SE is a biotechnology company focused on discovering and developing immunotherapies and other medicines, with a major commercial base in COVID-19 vaccines and a growing oncology pipeline.
Evommune, Inc.
EVMN · Pharmaceutical Preparations
ALX Oncology Holdings Inc
ALXO · Pharmaceutical Preparations
ALX Oncology Holdings Inc is a clinical-stage biotechnology company developing immuno-oncology therapies for cancer, headquartered in South San Francisco, California.
VolitionRX Limited
VNRX · In Vitro & In Vivo Diagnostic Substances
VolitionRx Ltd is a U.S.-based epigenetics diagnostics company developing blood-based tests that use nucleosomes and related biomarkers to detect and monitor disease.
CytomX Therapeutics, Inc.
CTMX · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment.
Last updated: 28/09/2026